Mediwatch is a small company destined to become a much bigger fish by the time this year is out. Mediwatch are already a market leader in urological medical diagnostics equipement and are currently exporting their products throughout the UK, Canada, Europe, India and Japan. That doesn't leave much of the globe left for them to capture - until you remember the good ol' US and China. These are the two massive markets which are destined to be added to MDW's export client portfolio by the end of 2005.

Website: www.mediwatch.com

The company is currently heavily undervalued. This is probably because Mediwatch's speciality is not a very glamourous business to be in as their equipment is used extensively to diagnose prostate cancer in men and other nasty urological conditions affecting both men and women. However, don't let that put you off investing in these guys. This is big business and is growing at an exponential rate as more and more people globally become health-aware as they get older. Mediwatch normally supply their products through to global markets via distribution agreements. They already have the best of distribution partners in the well known US medical distributor CR Bard who supply Canada and Europe and GE Medical who supply Japan. The UK business is handled by Mediwatch's own dedicated sales team. US FDA approval was gained for MDW's products at the start of last year, however a whole year of US legal wrangling meant that they were unable to seek a suitable partner for the crucial distribution agreement until the start of this year. This distribution agreement is expected by the board to have a "significant effect" on the share price so they are reluctant to give any clues as to when it will be signed, sealed and delivered. The general consensus is that this US distribution agreement will be announced in July/August. In China and Hong Kong, MDW have done things the other way round. They have set up distribution agreements with major Asian medical equipment distributors and have stock already out there waiting to sell into the markets - all they are waiting for is SDA approval (which is a "rubber stamp") from the Chinese authorities - this can take anything up to 12 months to come through and MDW applied during Autumn 2004 - so even more good news coming soon this year. Epidemiological data from British Association of Urology conference last year: On average 30-45% of all men between the age of 50 and 70 have at least one PSA test per year in the US / Italy / Australia. If that's not enough to convince you to invest a few hard earned coppers in MDW, they are also developing a PSA stick test product (PSAWatch) which is revolutionary and causing some excitement in medical circles. This product can also be adapted (at very low cost) for a whole spectrum of medical disciplines from Cardiology to Veterinary Practice! This product is likely to be released in the next few weeks. Philip Stimpson the CEO has said that this product is going to be their "gold mine" - I'm sure it will prove to be ours too.

Me too, anything <12p will be a bargain for the future.

Tick up this morning on not much volume..nice to see a bit of blue. Any news?

In the past couple of years during December and January it has been profitable to be a Mediwatch shareholder. I see no different this year, especially with the good news recently released and the run up towards interim results end of Jan.

Spot on
This share will double in price from this level no problem in 2006.imho

think we will be at the 17/18p mark,leading up to next results and that's without any further updates!

16p then,any offers :-)

Evening banjo, got a bit enthusuiastic on the news release, didn't quite pan out as expected so reckon I'll take it as it comes from now on. Still optimistic for the company though and TA still looking sound for a rise :-)

Morning Opto. We have had nearly all the news that we wanted,a lot of people getting confused that the PSAwatch is the key issue here.In one respect it is but the Multiscan is the hub for most of their devices,including the PSA testing.

The Multiscan has,as we know,got FDA/CE approval now,so this is the first and major stage complete in my view!

MDT would not have signed the deal if they were not going for the whole package,there are cheaper products out there for multiscanners after all but none that offer the PSA testing capabilities with the accuracy of MDW and with a 10 min. response time!

This appears to be a share that people cannot grasp the importance of what MDW has achieved over the last 2 years but it will come eventually,as many or more likely the few that have faith will reap rewards in the next year or so!

wasn't meant as a ramp by the way..just my view after lots of research!

.

MDW holding up well, maybe I won't get to top-up below 13p after-all.
The question is will current sales and future sales prevent another need for fund-raising?

Just thought i'd post this,always good to read again.

12th December 2005

British medical company announces FDA and CE approval on its new Multiscan product

Mediwatch UK Limited (AIM: MDW), the high-tech medical diagnostic equipment manufacturer and supplier has received FDA and CE approval on it's new Multiscan, a complete, portable urological diagnostic platform, providing clinicians with a variety of key measurements assessing bladder and prostate function.

These approvals will allow Mediwatch to sell the Multiscan into the USA, Europe and other countries around the world covered by these approvals.

With increasing life expectancy and an ageing population, prostate and bladder problems are among the fastest growing health concerns encountered by doctors today.

The ground-breaking MULTISCAN provides clinicians with mobile, real-time, ultrasound imaging, accurate measurement and organ volume calculation of the bladder, prostate and kidney.

Central component of a complete urological assessment system, the MULTISCAN can be a compact, all-in-one, stand alone diagnostic device or the main element of a diagnostic system, linking other devices which are manufactured by Mediwatch enabling clinicians to tailor investigations and improve patient throughput. Integrated Bluetooth enables wireless connectivity to facilitate state of the art communications and patient reports.

Said Mediwatch CEO Philip Stimpson "With the sales and marketing agreement signed with Medtronic Inc for the USA and other countries around the world obtaining FDA and CE approval is another milestone reached in the growth of our company where our technical expertise meets the demands of new screening techniques designed to diagnose disease areas at an earlier stage. Thus saving on costs hospitalisation and more importantly time, offering a better opportunity for an improved lifestyle for patients".




8th December 2005

Mediwatch PLC Placing

Mediwatch plc ("Mediwatch" or the "Company"), the AIM listed provider of novel medical and diagnostic products for prostate related and other urology diseases, announces that it has completed a placing of 4,277,265 new ordinary shares of 1p each in the Company at 11p per share to raise 470,500 (the "Placing") before expenses.

The placing was fully subscribed by investors and the directors. Philip Stimpson has agreed to subscribe for 136,363 ordinary shares, Dr. John Forrest has agreed to subscribe for 45,454 ordinary shares, Mark Emberton has agreed to subscribe for 45,454 ordinary shares, Omer Karim has agreed to subscribe for 381,818 ordinary shares, and Kevin Middis has agreed to subscribe for 90,909 ordinary shares pursuant to the Placing. The Placing is conditional upon admission of the ordinary shares to trading on AIM ("Admission"). Admission and dealing in the shares is expected to commence on 14th December 2005.

The shareholding interests of the Directors subscribing for shares pursuant to the Placing will, following Admission, be as follows:

Director Total Number of Shares % of enlarged issued share capital
Philip G Stimpson 15,661,363 16.16%
John R. Forrest 45,454 0.05%
Mark Emberton 2,295,454 2.37%
Omer Karim 6,251,781 6.62%
Kevin J. Middis 350,909 0.36%

Company employees and associates have agreed to subscribe for a total of 886,363 ordinary shares pursuant to the Placing.

The net proceeds of the placing will be used to complete the research and development on three products to commence marketing in early 2006 and to continue the research with a new antigen to be added to the PSA test strip facilitating a new application for the Bioscan reader.

It's going to be a cracking 2006 for MDW me thinks-all in my humble opinion of course

Nothing like being humble Banjo, but you could be right. Hope you make enough to finish your 'day job' :-)

Should be back up to 14p by tomorrow lunchtime,in my very humble opinion :-)

I do hope that you are very humbly correct Banjo :-)

Added today, 2006 could be a very good year for MDW.

Andy,nay will be,...a very very good year for MDW-in my humbly crumbly opinion

Just going to copy what i have done on t'other site if you dont mind?

A steady away type day today.

Just been reading last months statement again,it does look very good,hopefully this months results will start to move us in the right direction for the rest of the year and beyond.

Apologies in advance if everyone has read this.....but it does look nice!

12th December 2005

British medical company announces FDA and CE approval on its new Multiscan product

Mediwatch UK Limited (AIM: MDW), the high-tech medical diagnostic equipment manufacturer and supplier has received FDA and CE approval on it's new Multiscan, a complete, portable urological diagnostic platform, providing clinicians with a variety of key measurements assessing bladder and prostate function.

These approvals will allow Mediwatch to sell the Multiscan into the USA, Europe and other countries around the world covered by these approvals.

With increasing life expectancy and an ageing population, prostate and bladder problems are among the fastest growing health concerns encountered by doctors today.

The ground-breaking MULTISCAN provides clinicians with mobile, real-time, ultrasound imaging, accurate measurement and organ volume calculation of the bladder, prostate and kidney.

Central component of a complete urological assessment system, the MULTISCAN can be a compact, all-in-one, stand alone diagnostic device or the main element of a diagnostic system, linking other devices which are manufactured by Mediwatch enabling clinicians to tailor investigations and improve patient throughput. Integrated Bluetooth enables wireless connectivity to facilitate state of the art communications and patient reports.

Said Mediwatch CEO Philip Stimpson "With the sales and marketing agreement signed with Medtronic Inc for the USA and other countries around the world obtaining FDA and CE approval is another milestone reached in the growth of our company where our technical expertise meets the demands of new screening techniques designed to diagnose disease areas at an earlier stage. Thus saving on costs hospitalisation and more importantly time, offering a better opportunity for an improved lifestyle for patients".

The article below (well below) appears to be all over the net at the moment,doesn't effect MDW's product in anyway-imho.

The PSA Test is all we have at the moment with nothing to better it at the present time.

It has recently,over the last few years,been widely known that the PSA Test alone is not the answer but when used in conjuction with DRE and in conjuction with the individuals lifestyle/health,it is still a very important test and as said before all we have!

4. I'm very surprised at this article being highlighted so many times when looking through t'internet.....may be missing something but it's all old news re-formatted-imho

MDW's Multiscan is the centre of so many tests (in above announcement)which can be added to ie bought,to enable it to become a very powerfull bit of kit.....an all in one 'Near patient testing device'if you like.

My Father tells of (he manages to joke about it)going into local hospital for PSA test (every,think 3/4 months...)and seeing sad and worried men sat in waiting room waiting for results or deciding whether or not to have an operation and if so which one or in fact,not have one at all and see what happens!

MDW's 10 minute Prostate test (at the moment a test takes 7-10 days)that can be carried out in your local doctors surgery is a god send for all going through this terrible trauma.Cheaper and quicker results enable more tests to be carried out with more data obtained to give the specialist a better view of the actual state of the Prostate and along with the DRE will enable the correct decission for treatment.

Worth repeating again...As a CORUS worker we have always known about testicle cancer and how to check for lumps ect.Used to be nice on yearly medical if a young nurse wanted a feel for herself...alas no more...well no more young ones-lol.Last year on some course or other the head of medical dept.had a one hour
talk on health ect.and 10 minutes of that was on the Prostate and problems concerning it.This was a first for CORUS and was very impressed that i could get a PSA test when ever i liked.....scared at moment-lol.

PSA Testing is vital in deciding if an operation/treatment is required relating to the Prostate and MDW are or will be leading the way especially now with MDT backing,plus the Far East shortly (hopefully)

Excuse spelling....got excited after reading above announcement again!
***************************************************************************************
This is the article,by the way (read 4. above).

The reliability of a prostate cancer-screening test may be compromised by lifestyle and demographic factors, according to a new study published in the January 15, 2006 issue of CANCER

http://www.fightprostatecancer.org/site/News2?JServSessionIdr005=fauz0x1qq1.app1a&page=NewsArticle&id=6099&news_iv_ctrl=1001